Chapter/Section Purchase

1 Study Coverage
1.1 Overactive Bladder (OAB) Therapeutics Product Introduction
1.2 Global Overactive Bladder (OAB) Therapeutics Outlook 2017 VS 2022 VS 2028
1.2.1 Global Overactive Bladder (OAB) Therapeutics Sales in US$ Million for the Year 2017-2028
1.2.2 Global Overactive Bladder (OAB) Therapeutics Sales in Volume for the Year 2017-2028
1.3 United States Overactive Bladder (OAB) Therapeutics Outlook 2017 VS 2022 VS 2028
1.3.1 United States Overactive Bladder (OAB) Therapeutics Sales in US$ Million for the Year 2017-2028
1.3.2 United States Overactive Bladder (OAB) Therapeutics Sales in Volume for the Year 2017-2028
1.4 Overactive Bladder (OAB) Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Overactive Bladder (OAB) Therapeutics in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Overactive Bladder (OAB) Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Overactive Bladder (OAB) Therapeutics Market Dynamics
1.5.1 Overactive Bladder (OAB) Therapeutics Industry Trends
1.5.2 Overactive Bladder (OAB) Therapeutics Market Drivers
1.5.3 Overactive Bladder (OAB) Therapeutics Market Challenges
1.5.4 Overactive Bladder (OAB) Therapeutics Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Overactive Bladder (OAB) Therapeutics Market Segment by Type
2.1.1 Anticholinergic Agents
2.1.2 Beta-3 Adrenoreceptor Agonists
2.2 Global Overactive Bladder (OAB) Therapeutics Market Size by Type
2.2.1 Global Overactive Bladder (OAB) Therapeutics Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Overactive Bladder (OAB) Therapeutics Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Overactive Bladder (OAB) Therapeutics Market Size by Type
2.3.1 United States Overactive Bladder (OAB) Therapeutics Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Overactive Bladder (OAB) Therapeutics Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Overactive Bladder (OAB) Therapeutics Market Segment by Application
3.1.1 Hosptial
3.1.2 Clinci
3.1.3 Other
3.2 Global Overactive Bladder (OAB) Therapeutics Market Size by Application
3.2.1 Global Overactive Bladder (OAB) Therapeutics Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Overactive Bladder (OAB) Therapeutics Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Overactive Bladder (OAB) Therapeutics Market Size by Application
3.3.1 United States Overactive Bladder (OAB) Therapeutics Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Overactive Bladder (OAB) Therapeutics Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Overactive Bladder (OAB) Therapeutics Competitor Landscape by Company
4.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Company
4.1.1 Top Global Overactive Bladder (OAB) Therapeutics Manufacturers Ranked by Revenue (2021)
4.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Manufacturer (2017-2022)
4.1.3 Global Overactive Bladder (OAB) Therapeutics Sales by Manufacturer (2017-2022)
4.1.4 Global Overactive Bladder (OAB) Therapeutics Price by Manufacturer (2017-2022)
4.2 Global Overactive Bladder (OAB) Therapeutics Concentration Ratio (CR)
4.2.1 Overactive Bladder (OAB) Therapeutics Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Overactive Bladder (OAB) Therapeutics in 2021
4.2.3 Global Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Overactive Bladder (OAB) Therapeutics Manufacturing Base Distribution, Product Type
4.3.1 Global Overactive Bladder (OAB) Therapeutics Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Overactive Bladder (OAB) Therapeutics Product Type
4.3.3 Date of International Manufacturers Enter into Overactive Bladder (OAB) Therapeutics Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Overactive Bladder (OAB) Therapeutics Market Size by Company
4.5.1 Top Overactive Bladder (OAB) Therapeutics Players in United States, Ranked by Revenue (2021)
4.5.2 United States Overactive Bladder (OAB) Therapeutics Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Overactive Bladder (OAB) Therapeutics Sales by Players (2020, 2021 & 2022)
5 Global Overactive Bladder (OAB) Therapeutics Market Size by Region
5.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Overactive Bladder (OAB) Therapeutics Market Size in Volume by Region (2017-2028)
5.2.1 Global Overactive Bladder (OAB) Therapeutics Sales in Volume by Region: 2017-2022
5.2.2 Global Overactive Bladder (OAB) Therapeutics Sales in Volume Forecast by Region (2023-2028)
5.3 Global Overactive Bladder (OAB) Therapeutics Market Size in Value by Region (2017-2028)
5.3.1 Global Overactive Bladder (OAB) Therapeutics Sales in Value by Region: 2017-2022
5.3.2 Global Overactive Bladder (OAB) Therapeutics Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Overactive Bladder (OAB) Therapeutics Market Size YoY Growth 2017-2028
6.1.2 North America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Overactive Bladder (OAB) Therapeutics Market Size YoY Growth 2017-2028
6.3.2 Europe Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Overactive Bladder (OAB) Therapeutics Market Size YoY Growth 2017-2028
6.4.2 Latin America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Allergan
7.1.1 Allergan Corporation Information
7.1.2 Allergan Description and Business Overview
7.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Allergan Overactive Bladder (OAB) Therapeutics Products Offered
7.1.5 Allergan Recent Development
7.2 Astellas Pharma
7.2.1 Astellas Pharma Corporation Information
7.2.2 Astellas Pharma Description and Business Overview
7.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Products Offered
7.2.5 Astellas Pharma Recent Development
7.3 Hisamitsu Pharmaceutical
7.3.1 Hisamitsu Pharmaceutical Corporation Information
7.3.2 Hisamitsu Pharmaceutical Description and Business Overview
7.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
7.3.5 Hisamitsu Pharmaceutical Recent Development
7.4 Pfizer
7.4.1 Pfizer Corporation Information
7.4.2 Pfizer Description and Business Overview
7.4.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Pfizer Overactive Bladder (OAB) Therapeutics Products Offered
7.4.5 Pfizer Recent Development
7.5 Ferring
7.5.1 Ferring Corporation Information
7.5.2 Ferring Description and Business Overview
7.5.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Ferring Overactive Bladder (OAB) Therapeutics Products Offered
7.5.5 Ferring Recent Development
7.6 GlaxoSmithKline
7.6.1 GlaxoSmithKline Corporation Information
7.6.2 GlaxoSmithKline Description and Business Overview
7.6.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.6.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Products Offered
7.6.5 GlaxoSmithKline Recent Development
7.7 Ion Channel Innovations
7.7.1 Ion Channel Innovations Corporation Information
7.7.2 Ion Channel Innovations Description and Business Overview
7.7.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Products Offered
7.7.5 Ion Channel Innovations Recent Development
7.8 Kwang Dong Pharmaceutical
7.8.1 Kwang Dong Pharmaceutical Corporation Information
7.8.2 Kwang Dong Pharmaceutical Description and Business Overview
7.8.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
7.8.5 Kwang Dong Pharmaceutical Recent Development
7.9 Lanzhou Institute of Biological Products
7.9.1 Lanzhou Institute of Biological Products Corporation Information
7.9.2 Lanzhou Institute of Biological Products Description and Business Overview
7.9.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Products Offered
7.9.5 Lanzhou Institute of Biological Products Recent Development
7.10 Merck
7.10.1 Merck Corporation Information
7.10.2 Merck Description and Business Overview
7.10.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Merck Overactive Bladder (OAB) Therapeutics Products Offered
7.10.5 Merck Recent Development
7.11 ONO Pharmaceutical
7.11.1 ONO Pharmaceutical Corporation Information
7.11.2 ONO Pharmaceutical Description and Business Overview
7.11.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.11.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
7.11.5 ONO Pharmaceutical Recent Development
7.12 Sanofi
7.12.1 Sanofi Corporation Information
7.12.2 Sanofi Description and Business Overview
7.12.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Sanofi Products Offered
7.12.5 Sanofi Recent Development
7.13 Tengion
7.13.1 Tengion Corporation Information
7.13.2 Tengion Description and Business Overview
7.13.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Tengion Products Offered
7.13.5 Tengion Recent Development
7.14 Teva Pharmaceutical Industries
7.14.1 Teva Pharmaceutical Industries Corporation Information
7.14.2 Teva Pharmaceutical Industries Description and Business Overview
7.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Teva Pharmaceutical Industries Products Offered
7.14.5 Teva Pharmaceutical Industries Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Overactive Bladder (OAB) Therapeutics Industry Chain Analysis
8.2 Overactive Bladder (OAB) Therapeutics Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Overactive Bladder (OAB) Therapeutics Distributors
8.3 Overactive Bladder (OAB) Therapeutics Production Mode & Process
8.4 Overactive Bladder (OAB) Therapeutics Sales and Marketing
8.4.1 Overactive Bladder (OAB) Therapeutics Sales Channels
8.4.2 Overactive Bladder (OAB) Therapeutics Distributors
8.5 Overactive Bladder (OAB) Therapeutics Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer